Patrick Trucchio analyst

Currently out of the existing stock ratings of Patrick Trucchio, 536 are a BUY (98.71%), 4 are a SELL (0.74%), 3 are a HOLD (0.55%).

Patrick Trucchio

Work Performance Price Targets & Ratings Chart

Analyst Patrick Trucchio, carries an average stock price target met ratio of 17.16% that have a potential upside of 40.11% achieved within 153 days. Previously, Patrick Trucchio worked at BERENBERG.

Patrick Trucchio’s has documented 911 price targets and ratings displayed on 42 stocks. The coverage was on Healthcare, Financial Services sectors.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 21-Sep-2026.

Wall Street Analyst Patrick Trucchio

Analyst best performing recommendations are on ANRO (ALTO NEUROSCIENCE).
The best stock recommendation documented was for QURE (UNIQURE NV) at 9/8/2025. The price target of $70 was fulfilled within 50 days with a profit of $52.57 (301.61%) receiving and performance score of 60.32.

Average potential price target upside

ALLK Allakos ALNY Alnylam Pharmaceuticals ATAI ATAI Life Sciences BV CMPS Compass Pathways Plc FLXN Flexion Therapeutics MNK Mallinckrodt plc CYBN Cybin FSTX FStar Therapeutics FTRP Field Trip Health Ltd MNMD Mind Medicine VIR Vir Biotechnology ALT Altimmune ARWR Arrowhead Pharmaceuticals ARNA Arena Pharmaceuticals BNTC Benitec Biopharma Ltd ADR DMTTF Small Pharma FIXX Homology Medicines FRLN Freeline Therapeutics Holdings Plc GHRS GH Research PLC IMCR Immunocore Holdings Ltd LBPH Longboard Pharmaceuticals MIST Milestone Pharmaceuticals MSSTF Mindset Pharma PRGO Perrigo Company PLC SLN Silence Therapeutics PLC DTIL Precision BioSciences GOSS Gossamer Bio IVVD Invivyd ONCY Oncolytics Biotech QURE Uniqure NV SGMO Sangamo Therapeutics BEAM Beam Therapeutics HRMY Harmony Biosciences Holdings VYGR Voyager Therapeutics ENTA Enanta Pharmaceuticals SUPN Supernus Pharmaceuticals ALL The Allstate ANRO Alto Neuroscience ASMB Assembly Biosciences FR First Industrial Realty Trust NRXP NRX Pharmaceuticals PHVS Pharvaris BV

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$3

$1.79 (147.93%)

$3

2 years 7 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

2 years 3 months 13 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.21 (-17.36%)

$1.5

2 years 8 months 16 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

2 years 9 months 15 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.79 (643.80%)

3 years 4 months 22 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

Please expand the browser size to see the chart

Which stock is Patrick Trucchio most bullish on?

Potential upside of $235.28 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Patrick Trucchio most reserved on?

Potential downside of -$0 has been obtained for SLN (SILENCE THERAPEUTICS PLC)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?